138 related articles for article (PubMed ID: 10368645)
1. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
Abou-Issa HM; Alshafie GA; Curley RW; Wong MF; Clagett-Dame M; Repa JJ; Sikri V
Anticancer Res; 1999; 19(2A):999-1004. PubMed ID: 10368645
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
[TBL] [Abstract][Full Text] [Related]
4. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent.
Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE
Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515
[TBL] [Abstract][Full Text] [Related]
5. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mammary tumor growth by a novel nontoxic retinoid: chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide.
Alshafie GA; Walker JR; Curley RW; Clagett-Dame M; Highland MA; Nieves NJ; Stonerock LA; Abou-Issa H
Anticancer Res; 2005; 25(3c):2391-8. PubMed ID: 16082771
[TBL] [Abstract][Full Text] [Related]
8. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
[TBL] [Abstract][Full Text] [Related]
9. Effect of short-term administration of N-(4-hydroxyphenyl)-all-trans-retinamide on chemically induced mammary tumors.
Silverman J; Katayama S; Radok P; Levenstein MJ; Weisburger JH
Nutr Cancer; 1983; 4(3):186-91. PubMed ID: 6221232
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.
Abou-Issa H; Moeschberger M; el-Masry W; Tejwani S; Curley RW; Webb TE
Anticancer Res; 1995; 15(3):805-10. PubMed ID: 7645962
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
Walker JR; Alshafie G; Nieves N; Ahrens J; Clagett-Dame M; Abou-Issa H; Curley RW
Bioorg Med Chem; 2006 May; 14(9):3038-48. PubMed ID: 16412653
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis.
Koo KL; Tejwani GA; Abou-Issa H
Anticancer Res; 1996; 16(4A):1893-8. PubMed ID: 8712718
[TBL] [Abstract][Full Text] [Related]
14. Retinoids as chemopreventive agents for breast cancer.
Moon RC; Mehta RG; Detrisac CJ
Cancer Detect Prev; 1992; 16(1):73-9. PubMed ID: 1551141
[TBL] [Abstract][Full Text] [Related]
15. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DMBA-initiated rat mammary tumour development by 1-O-hexyl-2,3,5-trimethylhydroquinone, phenylethyl isothiocyanate, and novel synthetic ascorbic acid derivatives.
Futakuchi M; Hirose M; Miki T; Tanaka H; Ozaki M; Shirai T
Eur J Cancer Prev; 1998 Apr; 7(2):153-9. PubMed ID: 9818778
[TBL] [Abstract][Full Text] [Related]
17. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
[TBL] [Abstract][Full Text] [Related]
18. Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats.
Hakkak R; Korourian S; Shelnutt SR; Lensing S; Ronis MJ; Badger TM
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):113-7. PubMed ID: 10667471
[TBL] [Abstract][Full Text] [Related]
19. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model.
Saarinen NM; Huovinen R; Wärri A; Mäkelä SI; Valentín-Blasini L; Needham L; Eckerman C; Collan YU; Santti R
Nutr Cancer; 2001; 41(1-2):82-90. PubMed ID: 12094633
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Samy RP; Gopalakrishnakone P; Ignacimuthu S
Chem Biol Interact; 2006 Dec; 164(1-2):1-14. PubMed ID: 17064676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
